Develops drugs for rare blood diseases like WHIM syndrome and chronic neutropenia.
Jun 2026Revenue $8.67M/yrExpenses $96.6M/yr
No trendCash runway ≈ 2.3 years from Jun 2026
Figures by year
When will X4 Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $8.67M and expenses $96.6M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $6.50M | $93.4M | −$86.9M |
| Dec 2024 | $2.60M | $39.0M | −$36.4M |
| Dec 2023 | $0.00 | $108M | −$108M |
| Dec 2022 | $0.00 | $87.6M | −$87.6M |
| Dec 2021 | $0.00 | $85.1M | −$85.1M |
| Dec 2020 | $3.00M | $62.9M | −$59.9M |
| Dec 2019 | $0.00 | $51.7M | −$51.7M |
| Dec 2018 | $0.00 | $29.1M | −$29.1M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.